A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...

Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.

Neil Bressler, M.D., a professor of ophthalmology at Johns Hopkins and editor-in-chief of JAMA Ophthalmology, argued that complement inhibition for geographic atrophy is a game changer. His debating ...

Dr. Erin Theisen, who co-led the study, said this discovery could help treat many diseases where inflammation is a problem.

() -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.-based company's experimental drug, ...

Also called C3G, this rare kidney disease often affects children and young adults, but it can happen at any age. It has major impact on a person’s health and life. C3G has two forms: dense deposit ...

True or false: You can improve your C3 glomerulopathy symptoms and your kidney function with a high-sodium diet. National Kidney Foundation: “Complement 3 Glomerulopathy (C3G): Knowing the Signs and ...